TVM Capital invests in Recurv Pharma to advance novel taxane RP-001
Feb. 2, 2023
Recurv Pharma Inc. is set to receive investment of up to $24 million from TVM Capital Life Science GmbH to support development up to phase IIa proof of concept of RP-001 to treat solid tumors.